Interleukin-4 gene therapy - University of Pittsburgh

Drug Profile

Interleukin-4 gene therapy - University of Pittsburgh

Alternative Names: S4-IL4

Latest Information Update: 20 Nov 2007

Price : $50

At a glance

  • Originator University of Pittsburgh
  • Class Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer pain

Most Recent Events

  • 16 Jun 2003 Preclinical trials in Cancer pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top